Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Novartis International (Details)

v3.20.1
Licensing and Other Arrangements - Novartis International (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Sep. 30, 2015
item
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2019
USD ($)
Licensing and other arrangements            
Revenue from contracts with customers   $ 500 $ 8,026      
Novartis International | License Agreement            
Licensing and other arrangements            
Agreement termination prior written notice period 180 days          
Number of performance obligations | item 1          
Revenue from contracts with customers   0 $ 0 $ 10,000 $ 37,000  
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones   470,000        
Royalty payment period 10 years          
Contract assets   0       $ 0
Contract liabilities   0       0
Capitalized contract costs   $ 0       $ 0